MediWound Statistics
Total Valuation
MediWound has a market cap or net worth of $216.23 million. The enterprise value is $171.30 million.
Important Dates
The next estimated earnings date is Thursday, March 20, 2025, before market open.
| Earnings Date | Mar 20, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
MediWound has 10.79 million shares outstanding. The number of shares has increased by 15.46% in one year.
| Current Share Class | 10.79M |
| Shares Outstanding | 10.79M |
| Shares Change (YoY) | +15.46% |
| Shares Change (QoQ) | +13.28% |
| Owned by Insiders (%) | 1.04% |
| Owned by Institutions (%) | 38.67% |
| Float | 7.47M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 9.46 |
| Forward PS | 8.76 |
| PB Ratio | 5.99 |
| P/TBV Ratio | 6.17 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 8.69 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.11, with a Debt / Equity ratio of 0.19.
| Current Ratio | 2.11 |
| Quick Ratio | 1.99 |
| Debt / Equity | 0.19 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1.00 |
Financial Efficiency
Return on equity (ROE) is -83.40% and return on invested capital (ROIC) is -27.30%.
| Return on Equity (ROE) | -83.40% |
| Return on Assets (ROA) | -15.35% |
| Return on Invested Capital (ROIC) | -27.30% |
| Return on Capital Employed (ROCE) | -35.40% |
| Revenue Per Employee | $197,200 |
| Profits Per Employee | -$280,590 |
| Employee Count | 100 |
| Asset Turnover | 0.28 |
| Inventory Turnover | 5.17 |
Taxes
In the past 12 months, MediWound has paid $163,000 in taxes.
| Income Tax | 163,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +58.28% in the last 52 weeks. The beta is 0.81, so MediWound's price volatility has been lower than the market average.
| Beta (5Y) | 0.81 |
| 52-Week Price Change | +58.28% |
| 50-Day Moving Average | 17.91 |
| 200-Day Moving Average | 17.60 |
| Relative Strength Index (RSI) | 57.30 |
| Average Volume (20 Days) | 79,886 |
Short Selling Information
| Short Interest | 796,829 |
| Short Previous Month | 758,788 |
| Short % of Shares Out | 6.43% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 18.59 |
Income Statement
In the last 12 months, MediWound had revenue of $19.72 million and -$28.06 million in losses. Loss per share was -$2.93.
| Revenue | 19.72M |
| Gross Profit | 2.45M |
| Operating Income | -17.40M |
| Pretax Income | -12.55M |
| Net Income | -28.06M |
| EBITDA | -16.54M |
| EBIT | -17.40M |
| Loss Per Share | -$2.93 |
Full Income StatementBalance Sheet
The company has $45.56 million in cash and $6.46 million in debt, giving a net cash position of $39.10 million or $3.62 per share.
| Cash & Cash Equivalents | 45.56M |
| Total Debt | 6.46M |
| Net Cash | 39.10M |
| Net Cash Per Share | $3.62 |
| Equity (Book Value) | 34.24M |
| Book Value Per Share | 3.26 |
| Working Capital | 28.31M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$14.60 million and capital expenditures -$7.68 million, giving a free cash flow of -$22.28 million.
| Operating Cash Flow | -14.60M |
| Capital Expenditures | -7.68M |
| Free Cash Flow | -22.28M |
| FCF Per Share | -$2.06 |
Full Cash Flow StatementMargins
Gross margin is 12.42%, with operating and profit margins of -88.26% and -142.29%.
| Gross Margin | 12.42% |
| Operating Margin | -88.26% |
| Pretax Margin | -141.46% |
| Profit Margin | -142.29% |
| EBITDA Margin | -83.86% |
| EBIT Margin | -88.26% |
| FCF Margin | n/a |
Dividends & Yields
MediWound does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -15.46% |
| Shareholder Yield | -15.46% |
| Earnings Yield | -13.34% |
| FCF Yield | -10.59% |
Analyst Forecast
The average price target for MediWound is $25.00, which is 24.75% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $25.00 |
| Price Target Difference | 24.75% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | 41.32% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on December 20, 2022. It was a reverse split with a ratio of 0.1428571:1.
| Last Split Date | Dec 20, 2022 |
| Split Type | Reverse |
| Split Ratio | 0.1428571:1 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |